Purpose: There is an unmet need for treatment options in hepatocellular carcinoma (HCC).
Sorafenib is currently the only approved systemic treatment for HCC. Refametinib, an oral …

Purpose: Refametinib, an oral MEK inhibitor, has demonstrated antitumor activity in
combination with sorafenib in patients with RAS-mutated hepatocellular carcinoma (HCC) …

Background: There are no proven or approved second-line treatment options for patients
with advanced HCC. Based on promising activity in a second-line phase 2 study (Bruix, Eur …

Sorafenib is still the only systemic drug approved for the treatment of advanced
hepatocellular carcinoma (HCC). In recent years, several investigational agents mainly …

Introduction: Sorafenib is the standard of care for patients with advanced hepatocellular
carcinoma (HCC) and well preserved liver function. However, until recent approval of …

Regorafenib showed promising results as a second-line agent after sorafenib failure in
hepatocellular carcinoma patients. The aim of this meta-analysis was to evaluate the efficacy …

Background Regorafenib has been investigated for its efficacy and safety as a second-line
treatment in patients with advanced hepatocellular carcinoma (HCC). We assessed the …

Purpose We assessed the safety of the multikinase inhibitor regorafenib in patients with
hepatocellular carcinoma (HCC) that had progressed following first-line sorafenib. Patients …

Over the past ten years, sorafenib, a multikinase inhibitor, has been the only systemic agent
approved for first-line treatment of patients with unresectable hepatocellular carcinoma …

Regorafenib (Stivarga®), a small molecule inhibitor of multiple kinases, is the first drug to be
approved for the treatment of hepatocellular carcinoma (HCC) in patients who have …